Multiple studies have demonstrated the efficacy of targeting the Nogo-A/NgR1 pathway for functional recovery and neural repair after spinal cord trauma, ischemic stroke, optic nerve injury, and models of multiple sclerosis [11]. This evidence concerns the gene RTN4 and ischemic stroke.